Employees Retirement System of Texas Buys 132,800 Shares of Boston Scientific Corporation $BSX

Employees Retirement System of Texas raised its stake in Boston Scientific Corporation (NYSE:BSX) by 23.9% in the 4th quarter, HoldingsChannel reports. The fund owned 687,751 shares of the medical equipment provider’s stock after buying an additional 132,800 shares during the quarter. Employees Retirement System of Texas’ holdings in Boston Scientific were worth $65,577,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BSX. Murphy & Mullick Capital Management Corp grew its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. United Community Bank raised its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Colonial Trust Co SC lifted its holdings in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares in the last quarter. Finally, Bangor Savings Bank lifted its holdings in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Evercore cut their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. National Bank Financial set a $115.00 price target on Boston Scientific in a report on Monday, February 2nd. Mizuho lowered their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $57.65 on Wednesday. The firm has a fifty day moving average of $61.52 and a two-hundred day moving average of $79.54. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a market capitalization of $85.68 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 1.06 and a beta of 0.62. Boston Scientific Corporation has a 52 week low of $52.52 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company earned $0.75 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.